ABSTRACT

Paracoccidioidomycosis is the most important systemic and endemic mycosis in Latin America, Colombia is the second country with the highest number of cases. According to the clinical manifestations, the forms of presentation of this disease can be acute or chronic; the last one occurs in patients older than 30 years causing lung involvement, in skin and mucous membranes. The antifungal treatment is based on the administration of sulfa drugs and azole derivatives in cases of mild to moderate manifestations, and amphotericin B, which is reserved for patients with severe disease and requires in-hospital management. We present the case of a 66-year-old patient with severe pulmonary manifestations as the only manifestation of chronic paracoccidioidomycosis that did not respond initially to management with oral itraconazole, therefore management was offered with amphotericin B. In the absence of clear clinical criteria for hospitalization by pulmonary commitment, we consider that the clinical - radiological commitment must be taken into account when initiating early parenteral management.

KEYWORDS

Amphotericin B, clinical–radiological compromise, intrahospital management, pulmonary manifestations, chronic paracoccidioidomycosis.

REFERENCES

1. Ministerio de Salud y Protección Social. Sistema integral de información de la protección social (SISPRO) [Internet]. [cited 1/04/2018]. Available from: http://www.sispro.gov.co/Pages/Contruya%20Su%20Consulta/Prestaciones.aspx.

2. Torrado E, Castañeda E, de la Hoz F, Restrepo A. Paracoccidioidomicocis: definición de las áreas endémicas de Colombia. Biomedica 2000;20(4):327-334. doi: https://doi.org/10.7705/biomedica.v20i4.1076

3. Queiroz-Telles F, Escuissato DL. Pulmonary paracoccidioidomycosis. Semin Respir Criti Care Med 2011;32(6):764-774. doi: 10.1055/s-0031-1295724.

4. Restrepo A. El hábitat natural del hongo Paracoccidioides brasiliensis, ¿cómo trazar el límite entre lo rural y lo urbano? Biomédica 2014;34(1):2.

5. Theodoro RC, Texeira Mde M, Felipe MS, et al. Genus paracoccidioides: Species recognition and biogeographic aspects. PloS One 2012;7(5):e37694. doi: 10.1371/journal.pone.0037694.

6. Camacho E, Niño-Vega GA. Paracoccidioides Spp.: Virulence factors and immune-evasion strategies. Mediators Inflamm 2017;2017:5313691. doi: 10.1155/2017/5313691.

7. Martinez R. New trends in Paracoccidioidomycosis epidemiology. J Fungi (Basel) 2017;3(1). pii: E1. doi: 10.3390/jof3010001.

8. Marques SA. Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. An Bras Dermatol 2013;88(5):700-711. doi: 10.1590/abd1806-4841.20132463.

9. Shikanai-Yasuda MA. Paracoccidioidomycosis treatment. Rev Inst Med Trop Sao Paulo 2015;57 Suppl 19:31-37. doi: 10.1590/S0036-46652015000700007.

10. Freitas RM, Prado R, Prado FL, et al. Pulmonary paracoccidioidomycosis: radiology and clinical-epidemiological evaluation. Rev Soc Bras Med Trop 2010;43(6):651-656.

11. Quagliato Júnior R, Grangeia Tde A, Massucio RA, De Capitani EM, Rezende Sde M, Balthazar AB. Association between paracoccidioidomycosis and tuberculosis: reality and misdiagnosis. J Bras Pneumol 2007;33(3):295-300.

12. Gomes E, Wingeter MA, Svidzinski TI. Clinical-radiological dissociation in lung manifestations of paracoccidioidomycosis. Rev Soc Bras Med Trop 2008;41(5):454-458.

13. Peçanha PM, de Souza S, Falqueto A, et al. Amphotericin B lipid complex in the treatment of severe paracoccidioidomycosis: a case series. Int J Antimicrob Agents 2016;48(4):428-430. doi: 10.1016/j.ijantimicag.2016.06.011.

14. Yamaga LYI, Benard G, Watanabe T, et al. 67Ga scintigraphy for assessment of disease severity and treatment response in patients with Paracoccidioidomycosis. Clin Nucl Med 2018;43(5):305-310. doi: 10.1097/RLU.0000000000002017.